IO360º, Reporting on the Latest Progress for Cancer Immunotherapy Announces 2023 Keynotes, Plenary Sessions and a Full Day on IO Cell Therapy

Share Article

The Conference Forum announced the 9th annual IO360º summit’s 2023 keynotes and plenary sessions.

“With the field of cell therapy rapidly advancing with exciting data, it became necessary to dedicate a full day to cell therapy for cancer immunotherapies,” - Kate Woda, Director, Immuno-Oncology 360º

The Conference Forum announced the launch of the 9th annual Immuno-Oncology 360º Summit (IO360°) taking place February 7-10, 2023 at the New York Marriott at the Brooklyn Bridge, in Brooklyn, NY.

“With the field of cell therapy rapidly advancing with exciting data, it became necessary to dedicate a full day to cell therapy for cancer immunotherapies,” said Kate Woda, Director of Immuno-Oncology 360º. “We are pleased to expand the program, to allow for more keynote speakers, more presentations and ultimately more data that is pushing the field forward.”

The IO360° 2023 keynotes and featured speakers include:

Marcela Maus, MD, PhD, a pioneer in the area of adoptive cell therapy and Director of Cellular Immunotherapy at Massachusetts General Hospital will address mechanisms of action driving CAR-T cells, why some programs don’t seem to work, and what can be done to solve for those issues.

Isabelle Rivière, PhD, cell therapy manufacturing expert and Director, Cell Therapy and Cell Engineering Laboratory, Memorial Sloan Kettering Cancer Center will deliver a keynote marking the progress on cell therapy manufacturing to include autologous, allogeneic, in vivo and point-of-care products.

The most prestigious analyst in IO, Andrew Baum, MD, Citi’s Head of Global Healthcare and Managing Director, Equity Research for Citi, will return to the IO360º stage for his annual keynote, for what is next on the IO radar, and what his top 10 recommendations are.

Arjun Goyal, MD, Co-founder and Managing Director, Vida Ventures, will provide his perspective as an expert investor on the overview of the current market, its future and the impact of the IO cell therapy field.

Patient keynote, Oswald Peterson, will bring an extraordinary perspective as a Stage IV lung cancer survivor and will share his story from diagnosis through to immunotherapy treatments that saved his life.

The main plenary sessions for 2023 cover:

  • Cell Therapy
  • Discovery / Preclinical
  • Biomarkers / Assay Development
  • Translational Science
  • RNA Therapeutics
  • Clinical Developments
  • Imaging Advancements
  • Clinical Operations
  • Business Developments

For the first time a full day will be dedicated to cellular cancer immunotherapy, called IO Cell Therapy 360º. This will be chaired by Teri Foy, MD, PhD, BMS, Aiman Shalabi, PharmD, GSK, Michael Kalos, PhD, Next Pillar Consulting and Ramy Ibrahim, MD,

To learn more about the event, visit

About Immuno-Oncology 360º:
IO360˚ is an annual conference in NYC that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bre Bugbee
Follow >
Visit website